(Q44319719)

1 December 2017

title

Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts (English)

1 reference

1 December 2017

main subject

phase II clinical trial

0 references

10

P Fenaux

1 reference

1 December 2017

V Ribrag

1

1 reference

1 December 2017

F Suzan

2

1 reference

1 December 2017

C Ravoet

3

1 reference

1 December 2017

W Feremans

4

1 reference

1 December 2017

A Guerci

5

1 reference

1 December 2017

F Dreyfus

6

1 reference

1 December 2017

G Damaj

7

1 reference

1 December 2017

J M Vantelon

8

1 reference

1 December 2017

J H Bourhis

9

1 reference

1 December 2017

publication date

1 February 2003

1 reference

1 December 2017

1 reference

1 December 2017

volume

17

1 reference

1 December 2017

issue

2

1 reference

1 December 2017

page(s)

319-322

1 reference

Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS.

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402726

The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402726

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402726

Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402726

DNA topoisomerase I and II in cancer chemotherapy: update and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402726

An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402726

Combination therapy with irinotecan (CPT-11), mitoxantrone, and dexamethasone in relapsed or refractory non-Hodgkin's lymphoma: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402726

Treatment of adult T-cell leukaemia-lymphoma with irinotecan hydrochloride (CPT-11). CPT-11 Study Group on Hematological Malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402726

Myelodysplastic syndromes: a scoring system with prognostic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402726

7 January 2021

Myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402726

7 January 2021

Long-term follow-up of de novo myelodysplastic syndromes treated with intensive chemotherapy: incidence of long-term survivors and outcome of partial responders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402726

7 January 2021

Low-dose melphalan induces favourable responses in elderly patients with high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402726

7 January 2021

Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402726

7 January 2021

Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402726

7 January 2021

Phase I and pharmacokinetic trial of weekly CPT-11

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402726

7 January 2021

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402726

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2402726

1 reference

1 December 2017

1 reference